Treatment outcome of postoperative radiotherapy for retroperitoneal sarcoma

被引：15

作者：

Lee, Hyun Jin ^{[1
]}

Song, Si Yeol ^{[1
]}

Kwon, Tae-Won ^{[2
]}

Yook, Jeong Hwan ^{[2
]}

Kim, Song-Cheol ^{[2
]}

Han, Duck-Jong ^{[2
]}

Kim, Choung-Soo ^{[3
]}

Ahn, Hanjong ^{[3
]}

Chang, Heung Moon ^{[4
]}

Ahn, Jin-Hee ^{[4
]}

Jwa, Eun Jin ^{[1
]}

Lee, Sang-Wook ^{[1
]}

Kim, Jong Hoon ^{[1
]}

Choi, Eun Kyung ^{[1
]}

Shin, Seong Soo ^{[5
]}

Ahn, Seung Do ^{[1
]}

机构：

[1] Univ Ulsan, Coll Med, Dept Radiat Oncol, Asan Med Ctr, 86 Asanbyeongwon Gil, Seoul 138736, South Korea

[2] Univ Ulsan, Coll Med, Dept Surg, Asan Med Ctr, Seoul, South Korea

[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea

[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea

[5] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Radiat Oncol, Kangnung, South Korea

来源：

RADIATION ONCOLOGY JOURNAL | 2011年 / 29卷 / 04期

关键词：

Sarcoma; Retroperitoneal; Radiotherapy; Postoperative; Outcome;

D O I：

10.3857/roj.2011.29.4.260

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: To evaluate the treatment outcome and prognostic factor after postoperative radiotherapy in retroperitoneal sarcoma. Materials and Methods: Forty patients were treated with surgical resection and postoperative radiotherapy for retroperitoneal sarcoma from August 1990 to August 2008. Treatment volume was judged by the location of initial tumor and surgical field, and 45-50 Gy of radiation was basically delivered and additional dose was considered to the high-risk area. Results: The median follow-up period was 41.4 months (range, 3.9 to 140.6 months). The 5-year overall survival (OS) was 51.8% and disease free survival was 31.5%. The 5-year locoregional recurrence free survival was 61.9% and distant metastasis free survival was 50.6%. In univariate analysis, histologic type (p = 0.006) was the strongest prognostic factor for the OS and histologic grade (p = 0.044) or resection margin (p = 0.032) had also effect on the OS. Histologic type (p = 0.004) was unique significant prognostic factor for the actuarial local control. Conclusion: Retroperitoneal sarcoma still remains as a poor prognostic disease despite the combined modality treatment including surgery and postoperative radiotherapy. Selective dose-escalation of radiotherapy or combination of effective chemotherapeutic agent must be considered to improve the treatment result especially for the histopathologic type showing poor prognosis.

引用

页码：260 / 268

页数：9